AbbVie Inc. (ABBV) Stock Price Prediction
AI-generated price target with bull & bear cases · Re-evaluated every trading morning and evening
Our AI model’s current price target for ABBV is $273.25 — 7.3% above the latest price of $254.58.
Target vs 52-Week Range
Bull Case vs Bear Case
Bull Case
The bull case for ABBV rests on the continued strong performance and growth of its next-generation immunology drugs, Skyrizi and Rinvoq, which have secured patent protection extending to 2037 for Rinvoq. Successful integration and accretive contributions from recent strategic acquisitions, such as Apogee Therapeutics and Cerevel, along with continued advancements in its diverse pipeline in neuroscience and oncology, are expected to offset the impact of the Humira patent cliff. Raised full-year guidance and positive analyst sentiment underpin the potential for sustained revenue and earnings growth.
Bear Case
The bear case involves a more significant and faster erosion of sales from Humira and other mature products than currently anticipated. Increased competitive pressures in the immunology market and potential setbacks or delays in pipeline trial results or new drug approvals could negatively impact future financial performance and earnings growth. Additionally, the company's high debt levels and potential challenges with liquidity could pose risks, especially if new acquisitions do not generate expected returns or if pricing pressures intensify.
Model-assessed risk level: Medium
Key Catalysts to Watch
Continued robust growth and market penetration of Skyrizi and Rinvoq.
Successful advancement and approval of key pipeline assets, particularly in neuroscience and oncology.
Effective integration and positive financial contributions from recent acquisitions, including Apogee Therapeutics, ImmunoGen, and Cerevel.
Strategic management of patent expirations and competitive landscape for existing blockbusters.
New drug approvals and label expansions across therapeutic areas.
Technical Backdrop
RSI-14
65.2
50-Day MA
$230.46
200-Day MA
$220.48
From 52-Wk High
-2.5%
Full momentum breakdown: Is ABBV overbought or oversold?
Model Notes
AbbVie Inc. is a research-based biopharmaceutical company in a pivotal transition period, moving beyond the Humira era. The company is reshaping its portfolio through next-generation immunology drugs like Skyrizi and Rinvoq, strategic acquisitions, and global market expansion. AbbVie reported strong first-quarter 2026 financial results with robust portfolio growth across immunology and neuroscience, leading to a raised full-year adjusted diluted EPS guidance for 2026.
The technical outlook for ABBV appears positive. The stock is in a rising trend channel in the medium term, indicating increasing optimism among investors. Technical indicators, including MACD and several moving averages, suggest a 'Strong Buy' or 'Buy' signal. There is no significant resistance in the price chart, suggesting potential for continued upward movement. The Relative Strength Index (RSI) is around 64-65, generally indicating a buy or neutral position.
Current Street Context
July 16, 2026The AI price target for AbbVie is $271.75. Analyst sentiment is largely positive, with a "Moderate Buy" consensus from 25 analysts and a "Strong Buy" from 22 analysts, with an average 12-month price target ranging from $266.57 to $271.75. The highest price target is $300.00. AbbVie is scheduled to announce its Q2 2026 financial results on Friday, July 31, 2026, before market open. The company recently revised its Q2 and full-year 2026 adjusted diluted EPS guidance to include a $291 million acquired IPR&D and milestones expense, resulting in a $0.17 per share reduction. Key growth drivers to watch include continued strong performance from its immunology franchise (Skyrizi and Rinvoq) and neuroscience segment, alongside updates on pipeline integration and clinical milestones.
Frequently Asked Questions
What is the price target for ABBV?
How is this forecast generated?
How accurate are stock price predictions?
Will ABBV stock go up?
How often does the AI target change?
Methodology
The price target, bull and bear cases, and risk level are produced by an AI model that reviews ABBV’s fundamentals, technical posture, current news flow, and analyst commentary via live web search. It re-evaluates every trading morning and evening; the street-context commentary refreshes each trading evening.
Targets are estimates, not guarantees. No model reliably predicts short-term prices — treat this page as a structured summary of what current information might justify, alongside the risks that could break the thesis.
Not Financial Advice
This page is for education and information only. Indicators are mechanical calculations, AI commentary can contain errors, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a qualified financial advisor. See our full disclaimer.
Keep Digging on ABBV
AbbVie Inc. Overview
Price, chart, analysis & financials
ABBV: Overbought or Oversold?
Updated daily
ABBV: Why Is It Moving?
Updated daily
ABBV: Undervalued or Overvalued?
Updated daily
Same question, Healthcare peers